Travere Therapeutics Future Growth

Future criteria checks 5/6

Travere Therapeutics is forecast to grow earnings and revenue by 67.3% and 25.2% per annum respectively while EPS is expected to grow by 69.1% per annum.

Key information

67.3%

Earnings growth rate

69.1%

EPS growth rate

Biotechs earnings growth	24.9%
Revenue growth rate	25.2%
Future return on equity	n/a
Analyst coverage	Good
Last updated	28 May 2024

Recent future growth updates

Recent updates

Shareholders May Be More Conservative With Travere Therapeutics, Inc.'s (NASDAQ:TVTX) CEO Compensation For Now

May 02

Lacklustre Performance Is Driving Travere Therapeutics, Inc.'s (NASDAQ:TVTX) 29% Price Drop

Apr 20

Travere Therapeutics: Restructuring Away From Disaster

Jan 30

Travere Therapeutics (NASDAQ:TVTX) May Not Be Profitable But It Seems To Be Managing Its Debt Just Fine, Anyway

Jan 22

Travere Therapeutics, Inc.'s (NASDAQ:TVTX) Share Price Boosted 48% But Its Business Prospects Need A Lift Too

Dec 18

New Forecasts: Here's What Analysts Think The Future Holds For Travere Therapeutics, Inc. (NASDAQ:TVTX)

Aug 08

Is Travere Therapeutics (NASDAQ:TVTX) A Risky Investment?

Jun 09

It's Down 27% But Travere Therapeutics, Inc. (NASDAQ:TVTX) Could Be Riskier Than It Looks

May 05

Travere Therapeutics GAAP EPS of -$1.05 misses by $0.14, revenue of $54.2M beats by $4.7M

Aug 04

Travere Theraspeutics a new buy at Canaccord as a 'rare disease powerhouse'

Jul 14

Is Travere Therapeutics (NASDAQ:TVTX) Weighed On By Its Debt Load?

Jun 19

Travere Therapeutics: Strong Sell, Ticking Time Bomb, We Are Passing

Apr 11

Is Travere Therapeutics (NASDAQ:TVTX) A Risky Investment?

Feb 07

Travere Therapeutics: Tarpeyo's Approval Is Good News

Jan 31

Does Travere Therapeutics (NASDAQ:TVTX) Have A Healthy Balance Sheet?

Oct 07

Regulatory Uncertainty Holding Travere Therapeutics Down Despite PROTECT Study Success

Aug 30

Travere: Setback Presents Cautious Opportunity

Jul 18

Does Travere Therapeutics (NASDAQ:TVTX) Have A Healthy Balance Sheet?

Jul 09

Earnings and Revenue Growth Forecasts

NasdaqGM:TVTX - Analysts future estimates and past financials data (USD Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
12/31/2026	450	-7	-20	-35	10
12/31/2025	321	-151	-102	-146	15
12/31/2024	223	-281	-251	-270	15
3/31/2024	156	-416	-339	-318	N/A
12/31/2023	145	-376	-322	-280	N/A
9/30/2023	232	-320	-305	-264	N/A
6/30/2023	223	-315	-288	-245	N/A
3/31/2023	92	-352	-263	-212	N/A
12/31/2022	109	-331	-215	-186	N/A
9/30/2022	137	-297	-188	-159	N/A
6/30/2022	178	-249	-114	-87	N/A
3/31/2022	229	-202	-64	-44	N/A
12/31/2021	132	-217	-39	-15	N/A
9/30/2021	221	-250	-29	-2	N/A
6/30/2021	204	-237	-56	-27	N/A
3/31/2021	198	-224	-69	-40	N/A
12/31/2020	198	-169	-67	-43	N/A
9/30/2020	194	-78	-53	-33	N/A
6/30/2020	187	-92	-71	-54	N/A
3/31/2020	184	-105	-83	-67	N/A
12/31/2019	175	-146	-74	-58	N/A
9/30/2019	172	-124	-73	-57	N/A
6/30/2019	169	-142	-62	-47	N/A
3/31/2019	165	-125	-46	-31	N/A
12/31/2018	164	-103	-45	-25	N/A
9/30/2018	163	-113	-41	-22	N/A
6/30/2018	162	-76	-31	-12	N/A
3/31/2018	160	-67	-22	-4	N/A
12/31/2017	155	-60	N/A	7	N/A
9/30/2017	150	-51	N/A	0	N/A
6/30/2017	144	-70	N/A	-2	N/A
3/31/2017	138	-70	N/A	-3	N/A
12/31/2016	134	-48	N/A	-3	N/A
9/30/2016	127	-42	N/A	2	N/A
6/30/2016	121	101	N/A	-2	N/A
3/31/2016	112	89	N/A	2	N/A
12/31/2015	100	117	N/A	-1	N/A
9/30/2015	84	91	N/A	-7	N/A
6/30/2015	64	-33	N/A	-23	N/A
3/31/2015	46	4	N/A	-43	N/A
12/31/2014	28	-111	N/A	-46	N/A
9/30/2014	14	-95	N/A	-45	N/A
6/30/2014	6	-89	N/A	-32	N/A
3/31/2014	0	-105	N/A	-23	N/A
12/31/2013	N/A	-35	N/A	-18	N/A
9/30/2013	N/A	-36	N/A	-10	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: TVTX is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.4%).

Earnings vs Market: TVTX is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: TVTX is expected to become profitable in the next 3 years.

Revenue vs Market: TVTX's revenue (25.2% per year) is forecast to grow faster than the US market (8.5% per year).

High Growth Revenue: TVTX's revenue (25.2% per year) is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if TVTX's Return on Equity is forecast to be high in 3 years time

Travere Therapeutics Future Growth

Future criteria checks 5/6

Key information

Recent future growth updates

Forecast to breakeven in 2026

Consensus EPS estimates fall by 13%, revenue upgraded

Forecast to breakeven in 2026

Consensus EPS estimates upgraded to US$1.86 loss

Travere Therapeutics, Inc. Provides Revenue Guidance for the Fourth Quarter and Full Year 2023

Consensus EPS estimates fall by 35%

Recent updates

Forecast to breakeven in 2026

Consensus EPS estimates fall by 13%, revenue upgraded

New minor risk - Profitability

First quarter 2024 earnings: EPS and revenues miss analyst expectations

Forecast to breakeven in 2026

Shareholders May Be More Conservative With Travere Therapeutics, Inc.'s (NASDAQ:TVTX) CEO Compensation For Now

Travere Therapeutics, Inc. to Report Q1, 2024 Results on May 06, 2024

CSL Vifor and Travere Therapeutics Announces European Commission Approves FILSPARI® (sparsentan) for the Treatment of IgA Nephropathy

Lacklustre Performance Is Driving Travere Therapeutics, Inc.'s (NASDAQ:TVTX) 29% Price Drop

Travere Therapeutics to Present Abstracts on Filspari® (Sparsentan) in Iga Nephropathy At World Congress of Nephrology and the American Nephrology Nurses Association

Travere Therapeutics, Inc., Annual General Meeting, May 08, 2024

Travere Therapeutics, Inc. Submits Supplemental New Drug Application to U.S. Food and Drug Administration Seeking Full Approval of FILSPARI (Sparsentan) for Treatment of IgA Nephropathy

Travere Therapeutics, Inc. and Csl Vifor Announce Sparsentan Receives Positive Chmp Opinion for the Treatment of Iga Nephropathy

Full year 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Consensus EPS estimates upgraded to US$1.86 loss

Travere Therapeutics, Inc. to Report Q4, 2023 Results on Feb 15, 2024

President recently sold US$78k worth of stock

President notifies of intention to sell stock

Travere Therapeutics: Restructuring Away From Disaster

Travere Therapeutics (NASDAQ:TVTX) May Not Be Profitable But It Seems To Be Managing Its Debt Just Fine, Anyway

Travere Therapeutics, Inc. Provides Revenue Guidance for the Fourth Quarter and Full Year 2023

Travere Therapeutics, Inc.'s (NASDAQ:TVTX) Share Price Boosted 48% But Its Business Prospects Need A Lift Too

Travere Therapeutics Initiates Pivotal Phase 3 Clinical Trial of Pegtibatinase for the Treatment of Classical Homocystinuria (HCU)

Consensus EPS estimates fall by 35%

Travere Therapeutics, Inc. Completes Successful Pre-NDA Meeting for FILSPARI in IgAN

Consensus EPS estimates upgraded to US$1.55 loss

Consensus revenue estimates decrease by 16%, EPS upgraded

New major risk - Share price stability

Third quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Travere Therapeutics, Inc. Announces Late-Breaking Data from Phase 3 Studies of Sparsentan in IgAN and Fs Published in the Lancet and the NEJM Respectively and Presented At the American Society of Nephrology Kidney Week 2023

Travere Therapeutics, Inc. to Report Q3, 2023 Results on Nov 07, 2023

Travere Therapeutics Announces Confirmatory Data from the Phase 3 Protect Study of Filspari Demonstrating Long-Term Kidney Function Preservation in Iga Nephropathy; Narrowly Missing Egfr Total Slope Endpoint Versus Active Control, Irbesartan

Price target decreased by 17% to US$22.40

Mirum Pharmaceuticals, Inc. (NasdaqGM:MIRM) completed the acquisition of Bile Acid Product Portfolio from Travere Therapeutics, Inc. (NasdaqGM:TVTX).

Mirum Pharmaceuticals, Inc. (NasdaqGM:MIRM) completed the acquisition of Bile Acid Product Portfolio from Travere Therapeutics, Inc. (NasdaqGM:TVTX).

Consensus revenue estimates increase by 10%

New Forecasts: Here's What Analysts Think The Future Holds For Travere Therapeutics, Inc. (NASDAQ:TVTX)

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Travere Therapeutics, Inc. to Report Q2, 2023 Results on Aug 03, 2023

Is Travere Therapeutics (NASDAQ:TVTX) A Risky Investment?

Travere Therapeutics, Inc. Announces Positive Topline Results from Cohort 6 in the Phase 1/2 Compose Study of Pegtibatinase in Classical Homocystinuria

First quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

It's Down 27% But Travere Therapeutics, Inc. (NASDAQ:TVTX) Could Be Riskier Than It Looks

Price target decreased by 17% to US$29.33

Insufficient new directors

Consensus EPS estimates fall by 16%

Full year 2022 earnings: EPS in line with analyst expectations despite revenue beat

Price target increased by 7.2% to US$35.83

Travere Therapeutics Announces FDA Accelerated Approval of FILSPARI(sparsentan), the First and Only Non-Immunosuppressive Therapy for the Reduction of Proteinuria in IgA Nephropathy

Travere Therapeutics, Inc. to Report Q4, 2022 Results on Feb 23, 2023

Is Travere Therapeutics (NASDAQ:TVTX) A Risky Investment?

President notifies of intention to sell stock

Travere Therapeutics, Inc. Provides Financial Guidance for the Fourth Quarter and for the Fiscal Year 2022

President notifies of intention to sell stock

Third quarter 2022 earnings: EPS and revenues miss analyst expectations

Travere Therapeutics, Inc. to Report Q3, 2022 Results on Oct 27, 2022

Price target decreased to US$33.90

Travere Therapeutics Provides Regulatory Update on Its Sparsentan Program for Iga Nephropathy

Travere Therapeutics' FDA target action date for nephropathy treatment extended

Chief Commercial Officer recently sold US$78k worth of stock

Is Travere Therapeutics (NASDAQ:TVTX) Weighed On By Its Debt Load?

Travere Therapeutics: Changes In The Risk-Reward Assessment

Travere Therapeutics, Inc. and Csl Vifor Announce Ema Has Accepted for Review the Conditional Marketing Authorization Application for Sparsentan for the Treatment of Iga Nephropathy

Travere, CSL kidney disease drug sparsentan gets review in EU

Travere Therapeutics, Inc. Announces Executive Changes

Price target decreased to US$37.33

Second quarter 2022 earnings released: US$1.05 loss per share (vs US$0.64 loss in 2Q 2021)

Travere Therapeutics Provides Regulatory Updates on its Development Programs

Travere Therapeutics GAAP EPS of -$1.05 misses by $0.14, revenue of $54.2M beats by $4.7M